Clinical Trial Update: Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating elesclomol (STA-4783) in combination with paclitaxel versus paclitaxel alone for melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Elesclomol (STA-4783) (elesclomol)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Melanoma | Phase 3 | Status: TERMINATED